文献速递治疗药物监测与药物基因组学抗栓抗凝管理

基于电子病历与生物资源库的卒中患者氯吡格雷药物基因组学真实世界研究

Investigating Real-World Clopidogrel Pharmacogenetics in Stroke Using a Bioresource Linked to Electronic Medical Records.
PubMed 文献 · Clin Pharmacol Ther · 2017-09-19

本研究利用链接生物资源库的电子病历,纳入651例因动脉血栓闭塞事件住院后社区续用氯吡格雷的患者,随访24个月。CYP2C19*2功能缺失等位基因携带者主要终点(复发性动脉血栓闭塞或死亡)风险增加(HR=1.29;95%CI=1.04-1.59;P=0.019),缺血性卒中亚组风险更高(HR=2.23;95%CI=1.17-4.24;P=0.015)。

要点

  • CYP2C19*2功能缺失等位基因携带者复发性动脉血栓闭塞或死亡风险增加(HR=1.29;95%CI=1.04-1.59;P=0.019)。
  • 缺血性卒中亚组(n=94)风险估计更高(HR=2.23;95%CI=1.17-4.24;P=0.015)。
  • 纯电子病历方法可评估氯吡格雷药物基因组学的真实世界临床影响。

核心结论

  • CYP2C19*2功能缺失等位基因与氯吡格雷治疗患者复发性动脉血栓闭塞或死亡风险增加相关,缺血性卒中人群风险可能尤其高。

研究设计与样本

  • 利用链接生物资源库的电子病历开展的真实世界研究,纳入651例因任何动脉血栓闭塞事件住院后社区续用氯吡格雷处方的患者,随访24个月。

主要发现

  • 随访24个月期间,299例(46%)发生主要终点(复发性动脉血栓闭塞或死亡)。
  • CYP2C19*2功能缺失等位基因携带者主要终点风险增加(HR=1.29;95%CI=1.04-1.59;P=0.019)。
  • 缺血性卒中亚组(n=94)风险估计更高(HR=2.23;95%CI=1.17-4.24;P=0.015),并得到现有研究荟萃分析支持。

临床怎么用

  • 对缺血性卒中后使用氯吡格雷的患者,可考虑CYP2C19*2基因型信息以评估复发血栓风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Clopidogrel efficacy is influenced by genetic variation of cytochrome P450 (CYP)2C19, however, few studies have considered patients who have a stroke. We used electronic medical records (EMRs) linked to a bioresource to examine real-world implications of clopidogrel pharmacogenetics in stroke. Patients hospitalized for any arterial thrombo-occlusive (ATO) event who subsequently redeemed clopidogrel prescriptions in the community were entered into the study (n = 651). During 24-month follow-up, the primary endpoint of recurrent ATO or death occurred in 299 patients (46%). CYP2C19*2 loss-of-function allele carriers had an increased risk (hazard ratio (HR) = 1.29; 95% confidence interval (CI) = 1.04-1.59; P = 0.019). In the ischemic stroke subgroup (n = 94), the estimate of risk was greater (HR = 2.23; 95% CI = 1.17-4.24; P = 0.015), which was further supported by a meta-analysis of available studies. In conclusion, we have demonstrated the clinical impact of CYP2C19*2 on clopidogrel efficacy using a purely EMR approach. This suggests that the risk in the ischemic stroke population may be particularly high.

来源:Clin Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Tornio A, Flynn R, Morant S, et al. Investigating Real-World Clopidogrel Pharmacogenetics in Stroke Using a Bioresource Linked to Electronic Medical Records. Clin Pharmacol Ther. 2017. PMID: 28653333. doi:10.1002/cpt.780

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。